Genetic versus chemoprotective activation of Nrf2 signaling: Overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice

Carcinogenesis

Volumn 30, Issue 6, 2009, Pages 1024-1031

  Yates, Melinda S ^a   Tran, Quynh T ^b   Dolan, Patrick M ^a   Osburn, William O ^c   Shin, Soona ^a   McCulloch, Colin C ^d   Silkworth, Jay B ^d   Taguchi, Keiko ^e   Yamamoto, Masayuki ^e   Williams, Charlotte R ^f   Liby, Karen T ^f   Sporn, Michael B ^f   Sutter, Thomas R ^b   Kensler, Thomas W ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d GENERAL ELECTRIC COMPANY   (United States)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1[2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OYL]IMIDAZOLE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL PROTECTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DETOXIFICATION; GENE ACTIVATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; KNOCKOUT MOUSE; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TARGET CELL; WILD TYPE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CYTOSKELETAL PROTEINS; IMIDAZOLES; LIPID METABOLISM; LIVER; MALE; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; OLEANOLIC ACID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 66749112860     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp100     Document Type: Article

References (48)

1. Motohashi,H. et al. (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med., 10, 549-557.
2. Dinkova-Kostova,A.T. et al. (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl Acad. Sci. USA, 99, 11908-11913.
3. Kwak,M.K. et al. (2003) Modulation of gene expression by cancer chemo-preventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem., 278, 8135-8145.
4. Enomoto,A. et al. (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci., 59, 169-177.
5. Burton,N.C. et al. (2006) In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology, 27, 1094-1100.
6. Osburn,W.O. et al. (2007) Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int. J. Cancer, 121, 1883-1891.
7. Ramos-Gomez,M. et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl Acad. Sci. USA 98, 3410-3415.
8. Fahey,J.W. et al. (2002) Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo [a]pyrene-induced stomach tumors. Proc. Natl Acad. Sci. USA, 99, 7610-7615.
9. Xu,C. et al. (2006) Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res., 66, 8293-8296.
10. Yates,M.S. et al. (2007) Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther., 6, 154-162.
11. Yates,M.S. et al. (2006) Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-(2-cyano-3-,12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole. Cancer Res., 66, 2488-2494.
12. Liby,K. et al. (2007) The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res., 67, 2414-2419.
13. Sussan,T.E. et al. (2009) Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc. Natl Acad. Sci. USA, 106, 250-255.
14. Toyama,T. et al. (2007) Cytoprotective role of Nrf2/Keap1 system in methylmercury toxicity. Biochem. Biophys. Res. Commun., 363 645-650.
15. Okawa,H. et al. (2006) Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun., 339, 79-88.
16. Osburn,W.O. et al. (2008) Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol. Sci., 104, 218-227.
17. Singh,A. et al. (2006) Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med., 3, e420.
18. Nioi,P. et al. (2007) A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem. Biophys. Res. Commun., 362, 816-821.
19. Dinkova-Kostova,A.T. et al. (2005) Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc. Natl Acad. Sci. USA, 102 4584-4589.
20. Liby,K. et al. (2005) The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res., 65, 4789-4798.
21. Wakabayashi,N. et al. (2003) Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35, 238-245.
22. Honda,T. et al. (2002) A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana -1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett., 12, 1027-1030.
23. Kwak,M.K. et al. (2001) Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol. Med. 7, 135-145.
24. Livak,K.J. et al. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
25. Wu,Z. et al. (2004) A model-based background adjustment for oligonucleotide expression arrays. J. Am. Stat. Assoc., 99, 909-917.
26. Gautier,L. et al. (2004) affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 20, 307-315.
27. Silkworth,J.B. et al. (2008) Toxicogenomic analysis of gender, chemical, and dose effects in livers of TCDD- or aroclor 1254-exposed rats using a multifactor linear model. Toxicol. Sci., 102, 291-309.
28. Storey,J.D. (2003) The positive false discovery rate: A Bayesian interpretation and the q-value. Ann. Stat., 31, 2013-2035.
29. Nioi,P. et al. (2003) Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:qUinone oxidoreductase 1 gene: Reassessment of the ARE consensus sequence. Biochem. J., 374, 337-348.
30. Thimmulappa,R.K. et al. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res., 62, 5196-5203.
31. Han,E.S. et al. (2008) The in vivo gene expression signature of oxidative stress. Physiol. Genomics, 34, 112-126.
32. Hu,R. et al. (2006) Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci., 79, 1944-1955.
33. Nair,S. et al. (2006) Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Pharm. Res., 23, 2621-2637.
34. Primiano,T. et al. (1995) Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res., 55 4319-4324.
35. Chanas,S.A. et al. (2002) Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem. J., 365, 405-416.
36. Yang,X. et al. (2009) Gender disparity of hepatic lipid homeostasis regulated by the circadian clock. J. Biochem., 145 609-623.
37. Huang,Y. et al. (2006) Identification of novel transcriptional networks in response to treatment with the anticarcinogen 3H-1,2-dithiole-3-thione. Physiol. Genomics, 24, 144-153.
38. Pan,S.Y. et al. (2009) Energy intake, physical activity, energy balance, and cancer: Epidemiologic evidence. Methods Mol. Biol., 472, 191-215.
39. Calle,E.E. et al. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 348, 1625-1638.
40. Hursting,S.D. et al. (2007) Energy balance and carcinogenesis: underlying pathways and targets for intervention. Curr. Cancer Drug Targets, 7, 484-491.
41. Samudio,I. et al. (2006) A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: Direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol. Pharmacol., 69, 1182-1193.
42. Thimmulappa,R.K. et al. (2007) Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid. Redox Signal., 9, 1963-1970.
43. Liby,K.T. et al. (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer, 7, 357-369.
44. Wang,Y. et al. (2000) A synthetic triterpenoid, 2-cyano-3,12-dioxooleana- 1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol. Endocrinol., 14, 1550-1556.
45. Yore,M.M. et al. (2006) The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol. Cancer Ther., 5, 3232-3239.
46. Ahmad,R. et al. (2008) Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1) → signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res., 68, 2920-2926.
47. Liby,K. et al. (2008) Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin. Cancer Res., 14, 4556-4563.
48. Couch,R.D. et al. (2005) Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: Implications for a molecular mechanism of action. Bioorg. Med. Chem. Lett., 15, 2215-2219.